This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study,
evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and
preliminary clinical antitumor activity of XL114 administered alone orally to subjects with
Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the
recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.
Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.